Overview
"Syndrome with pulmonary hypertension as a major feature" is a grouping category used by Orphanet (ORPHA:275853) to classify rare genetic or developmental syndromes in which pulmonary hypertension (PH) is a prominent and defining clinical characteristic rather than a secondary or incidental finding. Pulmonary hypertension refers to abnormally elevated blood pressure in the pulmonary arteries, which carry blood from the heart to the lungs. Over time, this increased pressure forces the right side of the heart to work harder, potentially leading to right heart failure. Patients may experience progressive shortness of breath, fatigue, chest pain, dizziness, and swelling in the legs or abdomen. Because this is a classification group rather than a single discrete disease entity, it encompasses multiple rare syndromes where pulmonary hypertension is a major defining feature. These may include conditions caused by mutations in genes such as BMPR2, EIF2AK4, TBX4, and others, each with distinct inheritance patterns and associated clinical findings. The body systems most commonly affected include the cardiovascular system (particularly the pulmonary vasculature and right heart), the respiratory system, and in some syndromic forms, the skeletal, immune, or hematologic systems. Treatment depends on the specific underlying syndrome and typically involves pulmonary vasodilator therapies such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin pathway agents. Supportive care including supplemental oxygen, diuretics, and anticoagulation may also be employed. In severe or refractory cases, lung transplantation may be considered. Early diagnosis and management by a multidisciplinary team including pulmonologists, cardiologists, and clinical geneticists is essential for optimizing outcomes.
Variable
Can be inherited in different ways depending on the underlying gene
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
1 eventINOmax: FDA approved
In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availableINOmax
In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardi…
In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
Clinical Trials
View all trials with filters →No actively recruiting trials found for Syndrome with pulmonary hypertension as a major feature at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Syndrome with pulmonary hypertension as a major feature.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Syndrome with pulmonary hypertension as a major feature.
Community
No community posts yet. Be the first to share your experience with Syndrome with pulmonary hypertension as a major feature.
Start the conversation →Latest news about Syndrome with pulmonary hypertension as a major feature
No recent news articles for Syndrome with pulmonary hypertension as a major feature.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Syndrome with pulmonary hypertension as a major feature
What is Syndrome with pulmonary hypertension as a major feature?
"Syndrome with pulmonary hypertension as a major feature" is a grouping category used by Orphanet (ORPHA:275853) to classify rare genetic or developmental syndromes in which pulmonary hypertension (PH) is a prominent and defining clinical characteristic rather than a secondary or incidental finding. Pulmonary hypertension refers to abnormally elevated blood pressure in the pulmonary arteries, which carry blood from the heart to the lungs. Over time, this increased pressure forces the right side of the heart to work harder, potentially leading to right heart failure. Patients may experience pro
What treatment and support options exist for Syndrome with pulmonary hypertension as a major feature?
1 patient support program are currently tracked on UniteRare for Syndrome with pulmonary hypertension as a major feature. See the treatments and support programs sections for copay assistance, eligibility, and contact details.